Skip to main content
Clinical Trials/NCT05136235
NCT05136235
Not yet recruiting
Not Applicable

Pulmonary Hypertension in Extremely Preterm Infants - A Prospective Cohort Study

Universitair Ziekenhuis Brussel0 sites350 target enrollmentJanuary 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchopulmonary Dysplasia
Sponsor
Universitair Ziekenhuis Brussel
Enrollment
350
Primary Endpoint
Presence of pulmonary hypertension
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

Extremely preterm infants are at risk for developing bronchopulmonary dysplasia (BPD) and associated chronic pulmonary hypertension (PH), a consequence of altered pulmonary vasculature. This condition occurs in about 25% of babies with BPD, and the association grows with increasing BPD severity. Other risk factors have been described as well. Morbidity and mortality associated with prematurity and/or BPD increase significantly in the presence of PH.

Thus, international guidelines encourage the use of standardized screening protocols for this condition. However, several questions regarding these recommendations are left unanswered, such as a clear definition for PH in this population.

The research aim is to prospectively evaluate prevalence, risk factors and clinical course of PH in these children. The investigators aim to identify at-risk infants early on and ultimately improve survival making use of an early targeted intervention.

Registry
clinicaltrials.gov
Start Date
January 2022
End Date
December 2025
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Preterm infants with
  • Gestational age \<28 0/7 weeks
  • Birth weight \<1000 grams

Exclusion Criteria

  • Major congenital malformations
  • Structural airway or lung disease
  • Congenital heart disease
  • Lack of parental consent

Outcomes

Primary Outcomes

Presence of pulmonary hypertension

Time Frame: at 12 months of age

Pulmonary hypertension will be defined as one or more of the following echocardiographic findings: * Presence of a cardiac shunt with bidirectional or right-to-left flow * Estimated right ventricular systolic pressure (RVSP) \>40 mmHg * RVSP/systemic systolic blood pressure (SBP) ratio \>0.5 * Presence of ventricular septal wall flattening

Secondary Outcomes

  • PDA(at 36 weeks)
  • Sepsis(up to discharge from the NICU, an average of 16 weeks)
  • Birth weight(at birth)
  • ROP(at 36 weeks)
  • NEC(at 36 weeks)
  • VAP(at 36 weeks)
  • Presence of bronchopulmonary dysplasia(at 36 weeks PMA)
  • Gestational age(at birth)
  • Small for gestational age(at birth)
  • Oligohydramnios(at birth)
  • Maternal hypertensive disorders(at birth)

Similar Trials